Darwin AG: Darwin AG acquires all shares of MEDICOPHARM AG Munich, December

Munich, December 19, 2024 (pta023/19.12.2024/13:05 UTC+1)

Darwin AG (ISIN DE000A3C35W0) has acquired all shares of MEDICOPHARM AG Arzneimittel und Medikal Produkte (hereinafter "Medicopharm"), based in Nußdorf am Inn, with a purchase agreement dated today. Medicopharm is active in the manufacture and distribution of pharmaceuticals and thus complements Darwin AG's existing portfolio in this sector.

With the acquisition of the company, which was previously run as a family business, Darwin AG is expanding its existing competencies and structures in the area of pharmaceutical manufacturing, which was previously bundled in the subsidiary INOPHA GmbH, based in Ludwigsfelde. In the future, Darwin AG plans to leverage synergy potential here, particularly in the areas of purchasing and sales.

"By acquiring Medicopharm, we have succeeded in significantly improving our market position in the area of manufacturing and distribution of pharmaceuticals," said Chief Investment Officer Felix Bausch, commenting on the transaction. "We expect this to create synergies and a more dynamic growth perspective for both companies in the Darwin Group in the future, while retaining the existing locations of the subsidiaries," continued Felix Bausch.

According to the Management Board, the acquisition will have a significant impact on the Group's earnings situation from the 2025 financial year onwards. The parties have agreed not to disclose the financial details of the transaction.

Background

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analysis carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

(end)

Emitter:	Darwin AG Brienner Straße 7 80333 München Germany
Contact Person:	Daniel Wallerstorfer
Phone:	+49 89 20 500 450
E-Mail:	investor.relations@darwin-biotech.com
Website:	www.darwin-biotech.com
ISIN(s):	DE000A3C35W0 (Share)
Stock Exchange(s):	Free Market in Frankfurt, Munich (m:access)